Abstract

Objective: to determine the relative cost-effectiveness among statins in adult patients with dyslipidemia with predominant hypercholesterolemia to prevent cardiocerebrovascular events in Colombia, from the perspective of Colombian health system. Methods: a Markov model with quality-adjusted life years (QALY) gained as the main outcome, discount rate of 3% for both costs and outcomes, and five-year time horizon was built. Probabilities and costs were extracted from the literature and from official sources in the country, respectively. The threshold for cost-effectiveness was three times the 2012 per capita GDP. Univariate probabilistic, sensitivity analysis, threshold and acceptability curve were performed. Results: the average cost of statin therapy for a patient with dyslipidemia in five years is $3 472 733. The QALY gain was higher in rosuvastatin compared to other statins, however, it is the most costly strategy. Atorvastatin, which was second, is the most cost-effective. Conclusion: the most cost-effective intervention for patients with dyslipidemia with predominant hypercholesterolemia and indication of pharmacological management with moderate and high statin therapy in Colombia is atorvastatin
Translated title of the contributionCosto-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia
Original languageEnglish
Pages (from-to)118-124
JournalActa Medica Colombiana
Volume40
Issue number2
StatePublished - 15 Apr 2015

Keywords

  • cost-effectiveness analysis
  • statins
  • dyslipidemia
  • Colombia
  • economic analysis

Fingerprint

Dive into the research topics of 'Cost-effectiveness of statins for the treatment of dyslipidemia in Colombia'. Together they form a unique fingerprint.

Cite this